TScan Therapeutics, Inc.
TCRX
$1.53
$0.096.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.81% | 5.60% | -5.04% | -53.68% | 14.71% |
| Total Depreciation and Amortization | -30.77% | -7.97% | -11.00% | -2.03% | -0.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 98.77% | -42.86% | 23.53% | 126.14% | -42.44% |
| Change in Net Operating Assets | 1,984.95% | -112.78% | 203.51% | 65.97% | -121.82% |
| Cash from Operations | 1.81% | -6.46% | 10.39% | -23.15% | -396.45% |
| Capital Expenditure | 35.18% | -58.93% | -22.27% | -50.32% | 66.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 134.80% | -146.49% | -189.11% | 1,447.77% | 103.97% |
| Cash from Investing | 133.14% | -144.25% | -193.23% | 1,790.38% | 103.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -69.27% | -96.31% | 12,812.79% | 1,257.89% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | 100.00% |
| Cash from Financing | 3,614.63% | -99.24% | 62,530.62% | 1,257.89% | 107.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 141.79% | -207.28% | 1,320.83% | 132.77% | 59.30% |